# Ablatotech Signals: Putative Target Q6ZTQ4 in Severe Asthma
Background
Severe asthma is a chronic respiratory condition characterized by persistent symptoms and frequent exacerbations despite high-dose treatment. The complexity of its pathophysiology necessitates the discovery of novel molecular targets to improve therapeutic strategies. In this pursuit, the protein encoded by UniProt entry Q6ZTQ4 has been identified as a putative target that warrants further investigation.
Data-mining rationale
The identification of Q6ZTQ4 as a candidate target was achieved through a systematic cross-referencing of UniProt's reviewed human entries associated with severe asthma against 69 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). This data-mining approach aims to uncover potential targets that remain unexplored in clinical trials, as evidenced by the absence of Q6ZTQ4 in any registered Phase 1 or higher clinical programs.
Why prior analyses may have missed this
The GEO datasets analyzed in this study were generated before the adoption of advanced statistical methods like the empirical-Bayes approach implemented in the limma package. These older analyses may have lacked the statistical power to detect significant associations, potentially overlooking Q6ZTQ4 as a relevant target. By re-analyzing these datasets with limma and applying the Benjamini-Hochberg false discovery rate (FDR) correction, previously hidden associations may be revealed.
Reasoning for further validation
To confirm the potential of Q6ZTQ4 as a therapeutic target for severe asthma, the following experimental steps are recommended:
1. **Re-analysis of GEO datasets**: Utilize limma with an FDR threshold of < 0.05 to identify top differentially-expressed genes related to Q6ZTQ4.
2. **Validation in independent cohorts**: Conduct quantitative PCR (qPCR) to verify the differential expression of Q6ZTQ4 in an independent cohort of severe asthma patients.
3. **Tissue specificity assessment**: Explore the expression profile of Q6ZTQ4 across various tissues using resources like GTEx and the Human Protein Atlas to determine its relevance to lung pathology.
4. **Pathway context exploration**: Employ tools such as STRING and OmniPath to map the biological pathways involving Q6ZTQ4, providing insights into its functional role in severe asthma.
5. **Druggability assessment**: If validated, evaluate the druggability of Q6ZTQ4 using databases like DGIdb and ChEMBL to explore potential therapeutic interventions.
These steps are crucial for establishing Q6ZTQ4 as a viable target for severe asthma treatment and for guiding future drug development efforts.